TMCnet News
NeuroMetrix Reports Substantial Expansion of International Intellectual Property Assets for Quell Wearable Pain Relief TechnologyNeuroMetrix, Inc. (Nasdaq: NURO) reported today that Notices of Allowance has been issued for patents covering key technological features of the Company's Quell® Wearable Pain Relief Technology™ by the European Patent Office, the Japan Patent Office, and the State Intellectual Property Office of the People's Republic of China. The allowed patent claims address an essential element in the Company's proprietary technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers a novel calibration procedure that customizes nerve stimulation for each Quell user. In addition, the allowed patent claims protect the unique integrated Quell design that combines a neurostimulator, an electrode array, and an accelerometer. This technology enables automatic adjustment of nerve stimulation based on the user's position and movement, with applications such as optimizing therapy during sleep. The Company expects the three patents to formally issue by the third quarter of 2017. "We are pleased to have received these important Notice of Allowances for the Quell technology in the European Union, Japan and China. These are the three key expansion markets for the Quell business," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are currently in discussions with strategic partners about licensing or distributing Quell outside our core North American market. These patent caim allowances may help advance these discussions towards formal agreements."
About Quell
About NeuroMetrix View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005868/en/ |